Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate

References

• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-13; PMID:22395641; http://dx.doi.org/10.1093/jnci/djs033
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Terabe M, Wood LV. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol 2012; 39:348-57; PMID:22595057; http://dx.doi.org/10.1053/j.seminoncol.2012.02.002
   PubMed Web of Science ®Google Scholar
• Morera Y, Bequet-Romero M, Ayala M, Lamdan H, Agger EM, Andersen P, Gavilondo JV. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008; 11:381-93; PMID:19034678; http://dx.doi.org/10.1007/s10456-008-9121-5
   PubMed Web of Science ®Google Scholar
• Morera Y, Bequet-Romero M, Ayala M, Castro J, Puente P, Suárez J, et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010; 28:3453-61; PMID:20197134; http://dx.doi.org/10.1016/j.vaccine.2010.02.069
   PubMed Web of Science ®Google Scholar
• Morera Y, Bequet-Romero M, Ayala M, Pérez PP, Castro J, Sánchez J, Alba JS, Ancízar J, Cosme K, Gavilondo JV. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non-human primates. Vaccine 2012; 30:368-77; PMID:22075086; http://dx.doi.org/10.1016/j.vaccine.2011.10.082
   PubMed Web of Science ®Google Scholar
• Bequet-Romero M, Morera Y, Ayala-Ávila M, Ancizar J, Soria Y, Blanco A, Suárez-Alba J, Gavilondo JV. CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors. Vaccine 2012; 30:1790-99; PMID:22240345; http://dx.doi.org/10.1016/j.vaccine.2012.01.006
   PubMed Web of Science ®Google Scholar
• Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, Bequet-Romero M, Sánchez J, Valenzuela CM, Martín Y, et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 2014; 32:2241-50; PMID:24530151; http://dx.doi.org/10.1016/j.vaccine.2013.11.102
   PubMed Web of Science ®Google Scholar
• Mesa C, de LJ, Rigley K, Fernandez LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004;22:3045-52; PMID:15297054; http://dx.doi.org/10.1016/j.vaccine.2004.02.010
   PubMed Web of Science ®Google Scholar
• Mesa C, de LJ, Fernandez LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006; 24:2692-99; PMID:16316710; http://dx.doi.org/10.1016/j.vaccine.2005.08.111
   PubMed Web of Science ®Google Scholar
• Fernandez A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE, Bronte V. Inhibition of tumor-induced myeloid derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2011; 186:264-74; PMID:21135171; http://dx.doi.org/10.4049/jimmunol.1001465
   PubMed Web of Science ®Google Scholar
• Marrack Ph, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287-93; PMID:19247370; http://dx.doi.org/10.1038/nri2510
   PubMed Web of Science ®Google Scholar
• Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989; 121:134-45; PMID:2524278; http://dx.doi.org/10.1016/0008-8749(89)90011-7
   PubMed Web of Science ®Google Scholar
• Alonso DF, Farias EF, Urtreger A, Ladeda V, Vidal MC, Bal De Kier Joffe E. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. J Surg Oncol 1996; 62: 288-97; PMID:8691844; http://dx.doi.org/10.1002/(SICI)1096-9098(199608)62:4%3c288::AID-JSO14%3e3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012; 12:307-13; PMID:22378190; http://dx.doi.org/10.1038/nrc3246
   PubMed Web of Science ®Google Scholar
• Nitcheu Tefit, J, Vincent Serra, V. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev Vaccines 2011; 10:1207-20; PMID:21854313; http://dx.doi.org/10.1586/erv.11.84
   PubMed Web of Science ®Google Scholar
• Yaning W, David F, Martin V, An Song. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-45; PMID:15886877; http://dx.doi.org/10.1007/s10456-004-8272-2
   PubMedGoogle Scholar
• Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Seminars in Immunology 2000; 12:163-71; PMID:10910735; http://dx.doi.org/10.1006/smim.2000.0253
   PubMed Web of Science ®Google Scholar
• Baylor NW, Egan W, Richman P. Aluminum salts in vaccines-US perspective. Vaccine 2002; 20: S18-S23; PMID:12184360; http://dx.doi.org/10.1016/S0264-410X(02)00166-4
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 2004; 82:488-96; PMID:15479434; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x
   PubMed Web of Science ®Google Scholar
• Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 1985; 61:143-51; PMID:3876178
   PubMed Web of Science ®Google Scholar
• Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006; 42:3127-39; PMID:17098419; http://dx.doi.org/10.1016/j.ejca.2006.09.015
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6:465-77; PMID:19581909; http://dx.doi.org/10.1038/nrclinonc.2009.94
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288:371-8; PMID:9862791
   PubMed Web of Science ®Google Scholar
• Zor T, Selinger Z. “Linearization of the Bradford Protein Assay Increases Its Sensitivity: Theoretical and Experimental Studies.” Anal Biochem 1996; 236:302-8; PMID:8660509; http://dx.doi.org/10.1006/abio.1996.0171
   PubMed Web of Science ®Google Scholar
• Morera Y, Lamdan H, Bequet M, Ayala M, Rojas G, Muñoz Y, Gavilondo JV. Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein. Biotechnol Appl Biochem 2006; 44:45-53; PMID:16401185; http://dx.doi.org/10.1042/BA20050169
   PubMed Web of Science ®Google Scholar
• Zimmerman T, Petit Frère C, Satzger M, Raba M, Weisbach M, Döhn K, Popp A, Donzeau M. Simultaneous metal chelate affinity purification and endotoxin clearance of recombinant antibody fragments. J Immunol Methods 2006; 314:67-3; http://dx.doi.org/10.1016/j.jim.2006.05.012
   PubMed Web of Science ®Google Scholar